Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
| Revenue (Most Recent Fiscal Year) | $4.07B |
| Net Income (Most Recent Fiscal Year) | $560.12M |
| PE Ratio (Current Year Earnings Estimate) | 41.93 |
| PE Ratio (Trailing 12 Months) | 40.79 |
| PEG Ratio (Long Term Growth Estimate) | 3.81 |
| Price to Sales Ratio (Trailing 12 Months) | 2.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 5.67 |
| Pre-Tax Margin (Trailing 12 Months) | -16.91% |
| Net Margin (Trailing 12 Months) | -8.86% |
| Return on Equity (Trailing 12 Months) | 6.61% |
| Return on Assets (Trailing 12 Months) | 2.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.09 |
| Inventory Turnover (Trailing 12 Months) | 0.98 |
| Book Value per Share (Most Recent Fiscal Quarter) | $67.72 |
| Earnings per Share (Most Recent Fiscal Quarter) | $6.99 |
| Earnings per Share (Most Recent Fiscal Year) | $17.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.07 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.76M |
| Free Float | 58.15M |
| Market Capitalization | $10.46B |
| Average Volume (Last 20 Days) | 1.53M |
| Beta (Past 60 Months) | 0.30 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |